Rabu, 23 Maret 2022

Execs Are Snapping Up This Biotech Stock. Here’s Why You Should, Too

Dear Loyal Reader,

Turn Your Images On

Charles Mizrahi's No. 1 microcap for 2022 is seeing a flurry of insider buying by its CEO and CFO.

Typically, when a company's executives buy stock with their own cash — especially on the open market — we should pay close attention.

Because insider buying frequently means they foresee long-term gains ahead.

Charles recently did an interview with one of America's most respected journalists. They talked about this stock's future prospects … and why now is a great time to buy.

I won't spoil the surprise. Click here to learn more.

Click here if you are unable to see the image.

Regards,

Turn Your Images On
Lina Lee
Senior Managing Editor, Banyan Hill Publishing


 


(c) 2022 Banyan Hill Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Banyan Hill Publishing. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 866-584-4096) Legal Notice

The mailbox associated with this email address is not monitored, so please do not reply.

Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: http://banyanhill.com/contact-us

Remove your email from this list: Click here to Unsubscribe

Tidak ada komentar:

Posting Komentar